Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Research context
Helius Medical Technologies, Inc appears in PyInvesting’s Toronto Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Helius Medical Technologies, Inc is currently in a long term uptrend where the price is trading 9.6% above its 200 day moving average.
From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 32.7.
Helius Medical Technologies, Inc's total revenue rose by 25.7% to $191K since the same quarter in the previous year.
Its net income has increased by 52.4% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 52.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Helius Medical Technologies, Inc gets an overall score of 5/5.